Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Jun 05, 2019 4:30pm EDT
Atara Biotherapeutics Announces Collaborator Presentation Updating Positive Phase 1 Clinical Results for a Mesothelin-Targeted CAR T Immunotherapy in Patients with Advanced Mesothelioma Jun 04, 2019 9:36am EDT
Atara Biotherapeutics Presents Tab-cel® Clinical Biomarker Results and Nasopharyngeal Carcinoma Study Design at American Society of Clinical Oncology (ASCO) Annual Meeting Jun 01, 2019 9:00am EDT
Atara Biotherapeutics Appoints Pascal Touchon President, Chief Executive Officer and Member of the Board of Directors May 28, 2019 5:00pm EDT
Atara Biotherapeutics Announces Presentations Highlighting Tab-cel® and Mesothelin-Targeted CAR T Clinical Results at American Society of Clinical Oncology (ASCO) Annual Meeting May 15, 2019 5:05pm EDT
Atara Biotherapeutics Announces Presentation of Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) May 15, 2019 8:30am EDT
Atara Biotherapeutics Announces First Quarter 2019 Financial Results and Recent Operational Progress May 09, 2019 8:00am EDT
Atara Biotherapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019 May 07, 2019 4:41pm EDT
Atara Biotherapeutics Presents Off-the-Shelf, Allogeneic CAR T Preclinical Results at the American Association of Cancer Research (AACR) Annual Meeting 2019 Apr 01, 2019 4:10pm EDT
